Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Pain Management with Opioid Analgesics - How to Improve Efficacy, while Reducing Adverse Effects and Improve Patients’ Quality of Life

Author(s): Wojciech Leppert

Volume 25, Issue 30, 2019

Page: [3195 - 3196] Pages: 2

DOI: 10.2174/138161282530191010113245

Next »
[1]
Wang B, Downing NL. A crisis within an epidemic: critical opioid shortage in US hospitals. Postgrad Med J 2019. Epub ahead of print
[http://dx.doi.org/10.1136/postgradmedj–2018–136058] [PMID: 31217184]
[2]
Mercadante S. Opioid analgesics adverse effects - the other side of the coin. Curr Pharm Des 2019; 25(30): 3197-202.
[3]
Bennett M, Edwards H. Access to opioids for patients with advanced disease. Curr Pharm Des 2019; 25(30): 3203-8.
[4]
Kościelniak–Merak B, Batko I, Kobylarz K, Sztefko K, Kocot-Kępska M, Tomasik P. Impact of intravenous, perioperative - administrated lidocaine on postoperative serum levels of endogenous opioids in children. Curr Pharm Des 2019; 25(30): 3209-15.
[5]
Leppert W, Nosek K. Comparison of the quality of life of cancer patients with pain treated with oral controlled–release morphine and oxycodone and transdermal buprenorphine and fentanyl. Curr Pharm Des 2019; 25(30): 3216-24.
[6]
Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol 2016; 27: 1107-15.
[7]
Fallon M, Giusti R, Aielli F, et al. on behalf of ESMO Guidelines Committee. Management of cancer pain in adult patients:. ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29(suppl. 4): iv 149-74.

© 2024 Bentham Science Publishers | Privacy Policy